Adverse effects of first-line treatments for localized prostate cancer

Prospective data from a significant Spanish study provide us with additional insights into the short- and longer-term adverse effects of common types of invasive therapy for localized prostate cancer. … READ MORE …

Comparative data on first-line radiation therapy — and the lack thereof

The Agency for Healthcare Research and Quality (AHRQ) has released a draft version of a detailed techology assessment report entitled, “Comparative evaluation of radiation treatments for clinically localized prostate cancer: an update.” … READ MORE …

The role of surgery as first-line treatment for high-risk prostate cancer: Part III

Earlier this week we published reports on work from Memorial Sloan-Kettering Cancer Center and Johns Hopkins regarding the role of surgery as first-line treatment for men with high-risk prostate cancer. The topic appears to be coming into fashion. … READ MORE …

Is surgery best reserved for first-line treatment of higher-risk prostate cancers?

One of the characteristics of a great clinician is the ability to continue to learn, to revise one’s opinions, and even radically change one’s mind based on experience. And in a recent presentation to the New York Section of the American Urological Association, Scardino has again demonstrated these very specific capabilities. … READ MORE …

Hormone therapy not helpful for low-risk patients receiving first-line radiation

A report presented yesterday in Chicago, at the annual meeting of the American Society for Radiation Oncology (ASTRO), suggests that short-term hormone therapy given prior to and during first-line radiation treatment to intermediate-risk prostate cancer patients increases their chance of living longer, compared to those who receive radiation alone. However, the same study also showed that there is no significant benefit for low-risk patients. … READ MORE …

5-year biochemical recurrence rates after first-line cryotherapy

A recent publication has correlated nadir post-cryoablation PSA levels (i.e., the lowest PSA level achieved by the patient after treatment) with long-term biochemical disease-free survival in a risk-stratified cohort of patients with prostate cancer treated with cryoablation. … READ MORE …

First-line therapy for localized prostate cancer: outcomes and HRQOL

The decisions patients and their doctors make about which treatment to select as first-line therapy for localized prostate cancer are commonly based on perceptions and expectations about the side effects of these treatments, as well as on the curative potential of the therapy. … READ MORE …

An upper age limit for first-line treatment of localized disease?

For many years there has been intense discussion regarding who needs early detection and early (first-line) treatment for localized prostate cancer.

We know that many men have indolent disease (but we don’t know who or how many). We know that most men who are diagnosed with early stage, localized disease of low or intermediate risk will take several years to progress to metastatic disease and to show any significant signs or symptoms of that disease. And we know that many men who receive early treatment for localized prostate cancer have significant adverse effects (“harms”) that impact their quality of life. … READ MORE …